Emerging In Vitro Liver Technologies for Drug Metabolism and Inter-Organ Interactions
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
In vitro liver models provide essential information for evaluating drug metabolism, metabolite formation, and hepatotoxicity. Interfacing liver models with other organ models could provide insights into the desirable as well as unintended systemic side effects of therapeutic agents and their metabolites. Such information is invaluable for drug screening processes particularly in the context of secondary organ toxicity. While interfacing of liver models with other organ models has been achieved, platforms that effectively provide human-relevant precise information are needed. In this concise review, we discuss the current state-of-the-art of liver-based multiorgan cell culture platforms primarily from a drug and metabolite perspective, and highlight the importance of media-to-cell ratio in interfacing liver models with other organ models. In addition, we briefly discuss issues related to development of optimal liver models that include recent advances in hepatic cell lines, stem cells, and challenges associated with primary hepatocyte-based liver models. Liver-based multiorgan models that achieve physiologically relevant coupling of different organ models can have a broad impact in evaluating drug efficacy and toxicity, as well as mechanistic investigation of human-relevant disease conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 3×
“In a comprehensive study compiled from 150 compounds tested by 12 pharmaceutical companies, Olson et al.9 compared drug toxicities in humans to various animal species, including dog, primate, rat, mouse, and guinea pig.”
BackgroundInfluentialLee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells
Si-Tayeb, K., Noto, F. K., Nagaoka, M., Li, J., Battle, M. A., Duris, C., North, P. E., Dalton, S., & Duncan, S. A. (2010) · Hepatology · doi:10.1002/hep.23354 · Cited by 1,282
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Microscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219
Wilkening, S., Stahl, F., & Bader, A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.8.1035 · Cited by 794 · cited 1×
“In this regard, HepaRG cells have higher expression of key CYP450s than HepG2 cells, whose expression is usually low or undetectable.(13,15,16) Specifically, the most important and abundant isoform in the human liver, CYP3A4, is not detected at all in HepG2, and several key enzymes, including CYP1A2, CYP2A6, and CYP2B…”
BackgroundWagner, I., Materne, E.-M., Brincker, S., Süßbier, U., Frädrich, C., Busek, M., Sonntag, F., Sakharov, D. A., Trushkin, E. V., Tonevitsky, A. G., et al. (2013) · Lab on a Chip · doi:10.1039/c3lc50234a · Cited by 476 · cited 2×
“Wagner et al.67 used a Multi-Organ-Chip (MOC) with two compartments to model the 3D long-term stability of liver cells (HepaRG and hepatic stellate cells) and fresh skin biopsies.”
MethodGeneration of Functional Human Hepatic Endoderm From Human Induced Pluripotent Stem Cells
Sullivan, G. J., Hay, D. C., Park, I.-H., Fletcher, J., Hannoun, Z., Payne, C. M., Dalgetty, D., Black, J. R., Ross, J. A., Samuel, K., et al. (2010) · Hepatology · doi:10.1002/hep.23335 · Cited by 445
Why Drugs Fail - A Study on Side Effects in New Chemical Entities
Schuster, D., Laggner, C., & Langer, T. (2005) · Current Pharmaceutical Design · doi:10.2174/138161205774414510 · Cited by 417 · cited 1×
“It accounts for more than 50% of cases of acute liver failure and remains a major factor responsible for withdrawal or restriction of approved drugs.(1,2) Apart from hepatic toxicity, liver-generated metabolites are transported through systemic circulation to other tissues resulting in interaction with other organs, i…”
BackgroundGuo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J.-L., Green, B., Deng, H., Kaput, J., & Ning, B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035873 · Cited by 348
Cited by
Pelch, K., Wignall, J. A., Goldstone, A. E., Ross, P. K., Blain, R. B., Shapiro, A. J., Holmgren, S. D., Hsieh, J.-H., Svoboda, D., Auerbach, S. S., et al. (2019) · Toxicology · doi:10.1016/j.tox.2019.06.006 · Cited by 266
Fowler, S., Chen, W. L. K., Duignan, D. B., Gupta, A., Hariparsad, N., Kenny, J. R., Lai, W. G., Liras, J., Phillips, J. A., & Gan, J. (2020) · Lab on a Chip · doi:10.1039/c9lc00857h · Cited by 109
Liu, J., Li, R., Xue, R., Li, T., Leng, L., Wang, Y., Wang, J., Ma, J., Yan, J., Yan, F., et al. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800110 · Cited by 23
Bioprinting of hepatic tissue model using photocrosslinkable dECM-containing composite hydrogel
Tabatabaei Rezaei, N., Kumar, H., Liu, H., Rajeev, A., Natale, G., Lee, S. S., Park, S. S., & Kim, K. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101824 · Cited by 13
Metadata
- Authors
- Bale, S. S., Moore, L., Yarmush, M., & Jindal, R.
- Venue
- Tissue Engineering Part B: Reviews
- Publisher
- SAGE Publications
- Published
- 2016-10
- Volume
- 22
- Issue
- 5
- Pages
- 383-394
- ISSN
- 1937-3368 (ISSN-L)
- 1937-3376
- OpenAlex
- W2317397001
- Cited by
- 46
- References
- 20
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.